Related Experiment Videos
beta 2-Microglobulin and antiviral therapy for chronic hepatitis type B
R A de Man1, J Lindemans, S W Schalm
1Department of Internal Medicine II, Erasmus University Rotterdam, The Netherlands.
Antiviral Research
|May 1, 1989
Summary
Beta 2-microglobulin levels did not predict treatment success in patients with chronic hepatitis B receiving interferon therapy. Elevated pretreatment levels were common but did not correlate with HBe seroconversion outcomes.
Area of Science:
- Hepatology
- Virology
- Clinical Biochemistry
Background:
- Chronic hepatitis B virus (HBV) infection affects millions globally.
- Hepatitis B e-antigen (HBeAg) seroconversion is a key indicator of treatment success.
- Biomarkers for predicting treatment response are crucial for personalized therapy.
Purpose of the Study:
- To investigate the prognostic value of beta 2-microglobulin (B2M) and SGOT serum levels.
- To assess the utility of B2M in predicting HBe seroconversion during antiviral therapy.
- To evaluate the impact of interferon and descyclovir therapy on these markers.
Main Methods:
- A randomized controlled trial involving 36 patients with chronic HBe-positive hepatitis B.
- Measurement of serum beta 2-microglobulin and SGOT levels before and during therapy.
- Comparison of marker levels between treated patients and untreated controls.
- Analysis of marker levels in relation to treatment response (responders vs. non-responders).
Main Results:
- Elevated pretreatment beta 2-microglobulin levels were observed in 39% of patients.
- Significant differences in mean beta 2-microglobulin and SGOT levels were noted between treated and control groups after 4 and 8 weeks (P < 0.05).
- No significant difference in mean B2M or SGOT levels was found between responders and non-responders, indicating a lack of prognostic value.
Conclusions:
- Beta 2-microglobulin levels before or during interferon therapy do not predict the outcome of antiviral treatment for chronic HBe-positive hepatitis B.
- SGOT levels also did not show prognostic value in this patient cohort.
- Further research may be needed to identify reliable biomarkers for predicting treatment response in hepatitis B.